Focal Segmental Glomerulosclerosis Medical Services in China

Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by scarring (sclerosis) affecting only some (focal) glomeruli and only portions (segmental) of those affected glomeruli. It is not a single disease but rather a clinicopathologic syndrome with diverse underlying causes—including genetic mutations, viral infections (e.g., HIV), adaptive responses to reduced nephron mass, autoimmune dysregulation, and circulating permeability factors (e.g., soluble urokinase receptor, anti-CD40 antibodies). The pathogenesis involves podocyte injury and depletion, leading to disruption of the glomerular filtration barrier, proteinuria, and progressive glomerular collapse. Primary (idiopathic) FSGS is often mediated by circulating permeability factors that cause podocyte cytoskeletal rearrangement and foot process effacement; secondary forms arise from systemic conditions such as obesity, reflux nephropathy, sickle cell disease, or chronic hypertension. Epidemiologically, FSGS accounts for approximately 15–25% of adult-onset nephrotic syndrome cases in North America and Europe, and its incidence appears to be rising globally—particularly in Black populations, where genetic variants in the APOL1 gene confer markedly increased risk (up to 7–10-fold higher susceptibility). Other key risk factors include male sex, age 18–50 years, obesity (BMI ≥30), HIV infection, heroin use, and prior renal insults (e.g., reflux, obstruction). Clinically, patients commonly present with heavy proteinuria (>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia—though up to 30% may have subnephrotic proteinuria or even normal renal function at diagnosis. Hypertension and impaired GFR often develop as disease progresses. Without intervention, ~50% of untreated primary FSGS cases progress to end-stage kidney disease (ESKD) within 5–10 years. Quality of life is significantly impacted: persistent edema and fatigue limit physical activity; recurrent infections (due to immunosuppression and loss of immunoglobulins in urine) increase hospitalizations; dietary restrictions (low-sodium, low-protein), medication side effects (e.g., corticosteroid-induced weight gain, mood changes, osteoporosis), and financial burden of long-term care contribute to anxiety, depression, and social isolation. Children and young adults face particular psychosocial challenges related to school/work absenteeism, body image concerns, and fertility implications. Early diagnosis via kidney biopsy—and differentiation between primary, genetic, and secondary forms—is critical for guiding targeted therapy and prognostication.

Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by segmental scarring (sclerosis) affecting some, but not all, glomeruli. It represents a leading cause of nephrotic syndrome in adults and children and may progress to end-stage kidney disease (ESKD) if inadequately controlled. Management requires a multidisciplinary, individualized approach centered on reducing proteinuria, preserving glomerular filtration rate (GFR), mitigating cardiovascular risk, and addressing underlying etiologies—including primary (idiopathic), genetic, viral (e.g., HIV-associated), adaptive (e.g., obesity-related or post-renal ablation), and secondary forms (e.g., drug-induced or autoimmune-associated). Treatment strategies are stratified according to clinical presentation, histologic subtype, estimated GFR, proteinuria severity, and response to prior therapies.

Conservative treatment forms the cornerstone of FSGS management and must be initiated at diagnosis, regardless of pharmacologic intervention. This includes strict blood pressure control targeting <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) blockade—typically angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)—which reduce intraglomerular hypertension and proteinuria independent of antihypertensive effect. Dietary sodium restriction (<2 g/day) enhances RAAS inhibitor efficacy and attenuates edema and hypertension. A moderate-protein diet (0.8–1.0 g/kg/day) is recommended to minimize glomerular hyperfiltration without inducing malnutrition; high-protein diets (>1.3 g/kg/day) are contraindicated. Lipid-lowering therapy with statins is indicated for patients with nephrotic-range proteinuria and dyslipidemia to reduce cardiovascular morbidity. Fluid and weight monitoring, vaccination (especially pneumococcal and influenza), and avoidance of nephrotoxins—including NSAIDs, iodinated contrast, and herbal nephrotoxins (e.g., aristolochic acid)—are essential components of conservative care.

Pharmacotherapy is guided by disease classification and response. For primary (idiopathic) FSGS with nephrotic syndrome and preserved GFR (>60 mL/min/1.73m²), first-line immunosuppression consists of oral corticosteroids: prednisone 1 mg/kg/day (max 80 mg) for 4–6 weeks, followed by alternate-day taper over 4–6 months. Steroid resistance—defined as failure to achieve remission after ≥16 weeks of adequate dosing—warrants escalation to calcineurin inhibitors (CNIs): cyclosporine (3–5 mg/kg/day in two divided doses, targeting trough levels 100–150 ng/mL) or tacrolimus (0.05–0.1 mg/kg/day, trough 5–10 ng/mL), typically combined with low-dose prednisone (0.15 mg/kg every other day). Mycophenolate mofetil (MMF) (1–2 g/day) may serve as steroid-sparing agent or second-line option in CNI-intolerant patients. Emerging biologics—including rituximab (375 mg/m² weekly × 4 or 1 g × 2 doses 2 weeks apart) and abatacept—are under active investigation in refractory cases, particularly those with circulating permeability factors. For genetic or syndromic FSGS (e.g., mutations in NPHS1, NPHS2, TRPC6), immunosuppression is generally ineffective and avoided; management focuses on supportive care and timely renal replacement planning. In HIV-associated FSGS, antiretroviral therapy (ART) remains primary, with adjunctive RAAS inhibition.

Surgical treatment has no direct role in FSGS pathogenesis but becomes relevant in specific contexts. Nephrectomy is rarely indicated—only in rare cases of unilateral massive proteinuria with documented asymmetric disease and preserved contralateral function, which remains controversial and unsupported by robust evidence. More commonly, surgical intervention relates to complications: placement of tunneled dialysis catheters or arteriovenous fistulas for patients progressing to ESKD, or native kidney biopsy (percutaneous ultrasound-guided) for definitive diagnosis and subclassification—critical before initiating immunosuppression. In select patients with recurrent FSGS post-transplant (occurring in ~30–50% of primary FSGS recipients), preemptive plasmapheresis or rituximab may be employed perioperatively, though evidence remains limited.

China offers distinct advantages in FSGS management, rooted in integrated healthcare infrastructure, rapid diagnostic capacity, and innovation in therapeutics. Major tertiary hospitals—such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—house specialized glomerular disease centers with standardized biopsy protocols, electron microscopy, and immunofluorescence capabilities enabling precise histologic subtyping within 72 hours. China’s national registry for glomerular diseases facilitates real-world outcome tracking and informs evidence-based guidelines updated annually by the Chinese Society of Nephrology (CSN). Pharmacologically, domestically manufactured biosimilar CNIs and rituximab have significantly improved affordability and access; cost of a 6-month CNI regimen is approximately 30–50% lower than in Western markets. Moreover, China leads in clinical trials of novel agents—including anti-APOL1 therapies (in development for high-risk genetic variants) and targeted complement inhibitors—and hosts >25% of global FSGS interventional studies. Traditional Chinese Medicine (TCM) adjuncts—such as tripterygium glycosides (used cautiously under nephrology supervision)—are integrated into multimodal regimens where evidence supports synergistic antiproteinuric effects, though rigorous RCT data remain limited.

Recovery and long-term prognosis depend heavily on adherence, early intervention, and vigilant monitoring. Patients should undergo quarterly assessments including serum creatinine, estimated GFR, urinary protein-to-creatinine ratio (UPCR), serum albumin, lipid panel, and blood pressure. Sustained remission—defined as UPCR <0.3 g/g for ≥6 months—is associated with markedly slower eGFR decline. Lifestyle counseling must emphasize smoking cessation, structured aerobic exercise (150 min/week), and weight maintenance (BMI 18.5–24.9 kg/m²), especially in adaptive FSGS. Vaccination status should be reviewed annually; annual influenza and pneumococcal vaccines are mandatory. Psychosocial support—including access to certified renal dietitians and mental health professionals—is integral, given the chronic burden of nephrotic syndrome and immunosuppression. Women of childbearing potential require preconception counseling: ACEi/ARBs and CNIs are teratogenic and must be discontinued ≥3 months prior to conception; pregnancy is considered high-risk and necessitates co-management by nephrology and maternal-fetal medicine. Finally, patients with progressive eGFR decline (<45 mL/min/1.73m²) should be referred early to transplant evaluation, as preemptive transplantation confers superior survival versus dialysis initiation. With comprehensive, protocol-driven care, up to 60% of steroid-sensitive FSGS patients achieve sustained remission, and median time to ESKD exceeds 10 years in responsive cohorts.